Drugs / rHSA/GCSF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01919710 | Oct 2012 → Jun 2014 | cancer | Tianjin SinoBiotech Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rHSA/GCSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01919710 ↗ |
| Modality | Protein / enzyme biologic | “rHSA/GCSF fusion protein” NCT01919710 ↗ |